US › Healthcare

Altimmune Inc (ALT)

US · Healthcare · Biotechnology

$3.240.00%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Revenue YoY

-100.0%

Net profit

$-22.8M

EPS

$-0.12

EPS estimate

$-0.15

EPS came in at -0.12 against a street estimate of -0.15 — a beat of 20.0%.

Key statistics

Market cap

$630.2M

Forward P/E

8.2

P/B

1.32

Book value

$2.44

EPS (TTM)

$-0.76

52-week high

$6.44

52-week low

$2.56

50-day MA

$3.06

200-day MA

$3.59

Beta

0.18

Analyst view

Analysts rate Altimmune Inc a buy (8 buy, 1 hold, 0 sell out of 9) with an average price target of $17.22.

Shareholding

Insiders

0.42%

Institutions

77.76%

Largest institutional holders

Fund	Stake
Deep Track Capital, LP	9.90%
BlackRock Inc	6.58%
TCG Crossover Management, LLC	5.14%
State Street Corp	3.67%
Vanguard Capital Management, LLC	2.91%
Vanguard Portfolio Management, LLC	2.77%
Marshall Wace Asset Management Ltd	2.07%
Millennium Management LLC	1.70%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Altimmune Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.